TICKERNERD
Menu
QTTBQTTBHealthcare · Biotechnology

QTTB Stock Forecast: Q32 Bio, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$15
−1.43% on the day

The 5 Wall Street analysts covering Q32 Bio, Inc. hold a median 12-month price target of $38 — +150.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$451.0M
Ticker Nerd rank
86 / 100
Median analyst target
$38
Analysts covering
5
Total return, dividends reinvested
1W
−2.9%
1M
−17.9%
YTD
+356.3%
1Y
+705.9%
From 52W high
−29.1%
From 52W low
+812.7%
$2
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QTTB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Q32 Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Quality
89
Value
81
Revisions
69
Growth
63
Volatility
61
Issuance
57
Size
55
Accruals
17

Momentum (96): The shares have been drifting up relative to others.

Accruals (17): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QTTB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QTTB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26QTTBHigh $59Median $38Low $36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $36Median $38High $59

The green dot is the last close — the median target sits +150.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 July 2026HC Wainwright & Co.MaintainsBuy$13 → $36
13 July 2026OppenheimerMaintainsOutperform$20 → $40
13 July 2026OppenheimerMaintainsOutperform—
13 July 2026Wells FargoUpgradeOverweight$66
13 July 2026Wells FargoUpgradeOverweight—
22 May 2026MizuhoInitiatesOutperform$14
22 May 2026MizuhoInitiatesOutperform—
18 May 2026Cantor FitzgeraldInitiatesOverweight—
5 May 2026HC Wainwright & Co.ReiteratesBuy—
25 Feb 2026HC Wainwright & Co.InitiatesBuy—
12 Mar 2025Wells FargoMaintainsEqual-Weight—
11 Feb 2025BMO CapitalDowngradeMarket Perform—
11 Feb 2025Piper SandlerDowngradeNeutral—
12 Dec 2024BMO CapitalMaintainsOutperform—
12 Dec 2024GuggenheimDowngradeNeutral—
11 Dec 2024Leerink PartnersDowngradeMarket Perform—
11 Dec 2024OppenheimerMaintainsOutperform—
11 Dec 2024Piper SandlerMaintainsOverweight—
11 Dec 2024Raymond JamesDowngradeOutperform—
11 Dec 2024Wells FargoDowngradeEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QTTB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

QTTB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Q32 Bio, Inc. (QTTB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.8×

Cheaper than 66% of US stocks

Price / sales
8.4×

Cheaper than 17% of US stocks

Price / book
3.4×

Cheaper than 31% of US stocks

EV / EBITDA
16.0×

Cheaper than 22% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
39.9%

Higher than 92% of US stocks

Net margin
62.9%

Higher than 97% of US stocks

Returns & dividend
Return on equity
72.1%

Higher than 95% of US stocks

Return on assets
14.7%

Higher than 97% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

QTTB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
QTTBQ32 Bio, Inc.$451.0M
86
PBYIPuma Biotechnology, Inc.$449.4M
99
CABACabaletta Bio, Inc.$448.4M
28
OCGNOcugen, Inc.$457.0M
24
LRMRLarimar Therapeutics, Inc.$460.4M
35
RZLTRezolute, Inc.$440.2M
34
DNAGinkgo Bioworks Holdings, Inc.$439.8M
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Q32 Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QTTB news & analysis

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PRNewsWire · 5 Aug 2026positive

Q32 Bio reported second quarter 2026 financial results and corporate updates on August 5, 2026. The company announced positive bempikibart 36-week topline results from Part B of the SIGNAL-AA trial, continued enrollment in the open-label extension, plans for a registration-directed program in severe/very severe alopecia areata in the first half of 2027, and completed a $200 million public offering in July 2026. It reported cash and cash equivalents of $106.3 million as of June 30, 2026, which combined with offering proceeds is expected to fund operations through Phase 3 topline results.

Why it matters — The positive trial data, planned registration-directed program, and strengthened cash position give QTTB watchers a clearer picture of the company's financial runway and development path for bempikibart.

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

Zacks Investment Research · 31 July 2026positive

Zacks Investment Research reported that the consensus price target for Q32 Bio (QTTB) suggests a potential 186% upside, while noting that such price targets are often not reliable indicators. The article points to an upward trend in earnings estimate revisions as a more meaningful signal of possible near-term gains.

Why it matters — QTTB watchers would care because the article highlights shifting analyst earnings expectations, which can influence investor sentiment and stock movement regardless of whether the price target is achieved.

FAQ

Frequently asked questions about QTTB stock

What is the QTTB stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Q32 Bio, Inc. have a median 12-month price target of $38, with estimates ranging from $36 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QTTB stock a buy right now?

Of the 5 analysts covering Q32 Bio, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Q32 Bio, Inc. 86 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QTTB?

As at 15 Aug 2026, Q32 Bio, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will QTTB stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +150.8% from the last close, and Ticker Nerd's factor model ranks Q32 Bio, Inc. 86 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QTTB stock forecast for 2030?

No analyst covering Q32 Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QTTB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $59 over the next 12 months.

How has QTTB stock performed over the past year?

Q32 Bio, Inc. returned +705.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Q32 Bio, Inc. do?

Q32 Bio Inc. is a clinical-stage biotechnology company that develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases.

What is the latest news on QTTB?

The most recent item we track (PRNewsWire, 5 Aug 2026): "Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update". Q32 Bio reported second quarter 2026 financial results and corporate updates on August 5, 2026. The company announced positive bempikibart 36-week topline results from Part B of the SIGNAL-AA trial, continued enrollment in the open-label extension, plans for a registration-directed program in severe/very severe alopecia areata in the first half of 2027, and completed a $200 million public offering in July 2026. It reported cash and cash equivalents of $106.3 million as of June 30, 2026, which combined with offering proceeds is expected to fund operations through Phase 3 topline results.

Company

About Q32 Bio, Inc.

Q32 Bio Inc. is a clinical-stage biotechnology company that develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases. The company focuses on targeting potent regulators of both the adaptive and innate immune systems to re-balance immunity in conditions driven by pathological immune dysfunction. Its lead programs center on the IL-7 and thymic stromal lymphopoietin receptor pathways and the complement system, using antibody-based and tissue-targeted biologic approaches to address immune dysregulation in diseases such as alopecia areata and other severe inflammatory disorders. A key product candidate, bempikibart, is a fully human anti–IL-7 receptor alpha monoclonal antibody being evaluated in Phase 2 clinical trials for alopecia areata. Q32 Bio operates as a single biopharmaceutical segment focused on drug discovery and clinical development, primarily serving the U.S. market. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio today positions itself within the biotechnology and immunology sectors as a developer of next-generation immune therapeutics for chronic immune-mediated conditions.

CEO Ms. Jodie Pope Morrison · 22 employees · United States · https://www.q32bio.com